Edition:
India

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

6.00USD
20 Sep 2019
Change (% chg)

$-0.05 (-0.83%)
Prev Close
$6.05
Open
$6.07
Day's High
$6.33
Day's Low
$5.99
Volume
63,967
Avg. Vol
18,447
52-wk High
$9.76
52-wk Low
$3.60

Latest Key Developments (Source: Significant Developments)

Catabasis Pharmaceuticals Inc Quarterly Loss Per Share $0.62
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.62.CATABASIS PHARMACEUTICALS INC SAYS AS OF JUNE 30, 2019, THE COMPANY HAD AVAILABLE CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $46.1 MILLION.  Full Article

Catabasis Pharmaceuticals Reports Q2 Loss Per Share $0.62
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q2 LOSS PER SHARE $0.62.Q2 EARNINGS PER SHARE ESTIMATE $-0.61 -- REFINITIV IBES DATA.CATABASIS PHARMACEUTICALS - AS OF JUNE 30, CO HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $46.1 MILLION, VERSUS $51.7 MILLION AS OF MARCH 31, 2019.EXPECTS THAT IT HAS SUFFICIENT CASH TO FUND OPERATIONS BEYOND TOP-LINE PHASE 3 RESULTS AND THROUGH 2020.  Full Article

Catabasis Pharmaceuticals Reports Q4 Loss Per Share Of $0.85
Thursday, 14 Mar 2019 

March 14 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q4 LOSS PER SHARE $0.85.Q4 EARNINGS PER SHARE ESTIMATE $-0.90 -- REFINITIV IBES DATA.AS OF DECEMBER 31, 2018, CATABASIS HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $37.6 MILLION.  Full Article

Catabasis Pharmaceuticals reports third quarter financial results
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Catabasis Pharmaceuticals Inc :Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress.Q3 loss per share $0.31.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.Catabasis Pharmaceuticals Inc - co's current operating plan provides for cash to fund operations through august 2018​.  Full Article